T N Kakuda

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. ncbi request reprint Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine
    Srinivasan Ramanathan
    Gilead Sciences, Inc, Foster City, CA, USA
    Antivir Ther 13:1011-7. 2008
  2. pmc Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial
    Thomas Kakuda
    Janssen Research and Development, LLC, Clinical Pharmacology, 1125 Trenton Harbourton Road, Titusville, NJ 08560, USA
    AIDS Res Treat 2012:186987. 2012
  3. doi request reprint Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial
    T N Kakuda
    Janssen Research and Development LLC, Titusville, NJ, USA
    HIV Med 14:421-9. 2013
  4. doi request reprint Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteers
    Thomas N Kakuda
    Janssen Research and Development, LLC, Titusville, NJ, USA
    J Clin Pharmacol 53:41-50. 2013
  5. pmc Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials
    Thomas N Kakuda
    Tibotec, Inc, 1125 Trenton Harbourton Rd, K20605, Titusville, NJ 08560, USA
    Antimicrob Agents Chemother 55:2290-6. 2011
  6. doi request reprint Pharmacokinetic interactions between etravirine and non-antiretroviral drugs
    Thomas N Kakuda
    Tibotec, Inc, Titusville, New Jersey 08560 0200, USA
    Clin Pharmacokinet 50:25-39. 2011
  7. doi request reprint Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients
    T N Kakuda
    Tibotec, Inc, Titusville, New Jersey, USA
    Clin Pharmacol Ther 88:695-703. 2010
  8. doi request reprint Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine
    Thomas N Kakuda
    Tibotec Inc, Titusville, NJ, USA
    Antivir Ther 15:817-29. 2010
  9. ncbi request reprint Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients
    Thomas N Kakuda
    Tibotec Inc, Yardley, PA, USA
    Antivir Ther 13:655-61. 2008
  10. ncbi request reprint Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers
    T N Kakuda
    Tibotec Inc, Yardley, PA, USA
    HIV Med 10:173-81. 2009

Detail Information

Publications22

  1. ncbi request reprint Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine
    Srinivasan Ramanathan
    Gilead Sciences, Inc, Foster City, CA, USA
    Antivir Ther 13:1011-7. 2008
    ....
  2. pmc Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial
    Thomas Kakuda
    Janssen Research and Development, LLC, Clinical Pharmacology, 1125 Trenton Harbourton Road, Titusville, NJ 08560, USA
    AIDS Res Treat 2012:186987. 2012
    ..Conclusions. Population pharmacokinetics showed no relevant differences in darunavir or etravirine exposure by assessed covariates. Lower etravirine exposures were associated with lower response rates...
  3. doi request reprint Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial
    T N Kakuda
    Janssen Research and Development LLC, Titusville, NJ, USA
    HIV Med 14:421-9. 2013
    ..Artemether has an active metabolite, dihydroartemisinin. The objective was to investigate pharmacokinetic interactions between darunavir/ritonavir or etravirine and arthemether/lumefrantrine...
  4. doi request reprint Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteers
    Thomas N Kakuda
    Janssen Research and Development, LLC, Titusville, NJ, USA
    J Clin Pharmacol 53:41-50. 2013
    ..Pharmacokinetic interactions between etravirine and fluconazole or voriconazole are not expected to be clinically relevant; no dose adjustments are required during coadministration...
  5. pmc Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials
    Thomas N Kakuda
    Tibotec, Inc, 1125 Trenton Harbourton Rd, K20605, Titusville, NJ 08560, USA
    Antimicrob Agents Chemother 55:2290-6. 2011
    ..i.d. with etravirine in the absence of a potent inhibitor of cytochrome P450 3A (CYP3A) (i.e., a boosted protease inhibitor) or at 150 mg b.i.d. when coadministered with darunavir-ritonavir with or without etravirine...
  6. doi request reprint Pharmacokinetic interactions between etravirine and non-antiretroviral drugs
    Thomas N Kakuda
    Tibotec, Inc, Titusville, New Jersey 08560 0200, USA
    Clin Pharmacokinet 50:25-39. 2011
    ....
  7. doi request reprint Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients
    T N Kakuda
    Tibotec, Inc, Titusville, New Jersey, USA
    Clin Pharmacol Ther 88:695-703. 2010
    ..Factors other than the pharmacokinetics of etravirine such as the characteristics of the patients and the disease, as well as characteristics of the treatment regimen, predict virologic response...
  8. doi request reprint Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine
    Thomas N Kakuda
    Tibotec Inc, Titusville, NJ, USA
    Antivir Ther 15:817-29. 2010
    ..In conclusion, etravirine can be combined with most antiretrovirals, with no clinically meaningful effect on drug exposure or safety/tolerability profiles...
  9. ncbi request reprint Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients
    Thomas N Kakuda
    Tibotec Inc, Yardley, PA, USA
    Antivir Ther 13:655-61. 2008
    ..An open-label, randomized, crossover study to evaluate the pharmacokinetics of two different formulations of etravirine after single and multiple dosing...
  10. ncbi request reprint Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers
    T N Kakuda
    Tibotec Inc, Yardley, PA, USA
    HIV Med 10:173-81. 2009
    ..Two open-label, randomized, cross-over trials in healthy volunteers were conducted to investigate the pharmacokinetic interaction between etravirine and tenofovir disoproxil fumarate...
  11. pmc Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects
    Matt S Anderson
    Department of Clinical Pharmacology, Merck and Co, Inc, RY34A 500, P O Box 2000, Rahway, NJ 07065, USA
    Antimicrob Agents Chemother 52:4228-32. 2008
    ..Coadministration of etravirine and raltegravir was generally well tolerated; the data suggest that no dose adjustment for either drug is necessary...
  12. ncbi request reprint 7th International Workshop on Clinical Pharmacology of HIV Therapy 20-22 April 2006, Lisbon, Portugal
    Thomas N Kakuda
    Tibotec, Inc, 1020 Stony Hill Road, Suite 300, Yardley, PA 19067, USA
    Expert Opin Pharmacother 7:1519-33. 2006
    ..In total, 87 abstracts were accepted for presentation at the meeting: 29 oral and 58 poster presentations. This article highlights select presentations from the workshop...
  13. ncbi request reprint Effect of food and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteers
    Thomas N Kakuda
    Hoffman La Roche Inc, Nutley, New Jersey, USA
    Pharmacotherapy 26:1060-8. 2006
    ..To assess the relative bioavailability of saquinavir after administration with ranitidine alone, ranitidine and food, and food alone; and to investigate the mechanism underlying the effects of pH and food on saquinavir absorption...
  14. ncbi request reprint Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers
    Monika Schöller-Gyüre
    Research and Development, Tibotec BVBA, Mechelen, Belgium
    Antivir Ther 12:789-96. 2007
    ..To evaluate the pharmacokinetics of TMC125 (etravirine) and darunavir (DRV) with low-dose ritonavir (DRV/r)...
  15. ncbi request reprint Drug interactions between HIV protease inhibitors and acid-reducing agents
    Ronald W Falcon
    Tibotec Therapeutics, Bridgewater, New Jersey 08807, USA
    Clin Pharmacokinet 47:75-89. 2008
    ..Clinicians should be aware of the potential drug-drug interactions between some protease inhibitors and acid-reducing agents...
  16. doi request reprint Pharmacokinetic and pharmacodynamic study of the concomitant administration of methadone and TMC125 in HIV-negative volunteers
    Monika Schöller-Gyüre
    Tibotec BVBA, Generaal De Wittelaan L11B 3, Mechelen, Belgium
    J Clin Pharmacol 48:322-9. 2008
    ..TMC125 has no clinically relevant effect on the pharmacokinetics or pharmacodynamics of methadone. No dose adjustment for methadone is anticipated when coadministered with TMC125...
  17. doi request reprint Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers
    Monika Peeters
    Tibotec BVBA, Mechelen, Belgium
    Ann Pharmacother 42:757-65. 2008
    ..In vitro and in vivo studies have shown that etravirine is not associated with proarrhythmic potential. Electrocardiograms (ECGs) from healthy and HIV 1-infected volunteers showed no clinically relevant changes...
  18. doi request reprint Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults
    Monika Schöller-Gyüre
    Tibotec BVBA, Mechelen, Belgium
    Clin Ther 32:328-37. 2010
    ..Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) with activity against both wild-type HIV and viruses harboring NNRTI resistance. Etravirine is mainly eliminated via the hepatobiliary route...
  19. doi request reprint Clinical pharmacokinetics and pharmacodynamics of etravirine
    Monika Schöller-Gyüre
    Tibotec BVBA, Generaal De Wittelaan L11B 3, Mechelen B 2800, Belgium
    Clin Pharmacokinet 48:561-74. 2009
    ..In the two phase III trials DUET-1 and DUET-2, no relationship was demonstrated between the pharmacokinetics of etravirine and the primary efficacy endpoint of viral load below 50 copies/mL or the safety profile of etravirine...
  20. doi request reprint Effect of steady-state etravirine on the pharmacokinetics and pharmacodynamics of ethinylestradiol and norethindrone
    Monika Schöller-Gyüre
    Research and Development, Tibotec BVBA, B 2800 Mechelen, Belgium
    Contraception 80:44-52. 2009
    ..Etravirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant HIV, is an inducer of CYP3A4 and an inhibitor of CYP2C9/19...
  21. pmc A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers
    Monika Schöller-Gyüre
    Tibotec BVBA, Mechelen, Belgium
    Br J Clin Pharmacol 66:508-16. 2008
    ..This study evaluated the effect of steady-state omeprazole and ranitidine on the pharmacokinetics of a single dose of etravirine...
  22. ncbi request reprint The 5(th) International Workshop on Clinical Pharmacology of HIV Therapy
    Thomas N Kakuda
    Roche Laboratories, Inc, 340 Kingsland Street, Nutley, NJ 07110 1199, USA
    Expert Opin Pharmacother 5:1639-50. 2004
    ..A total of 31 oral and 48 poster presentations were accepted to this meeting, the largest number of accepted submissions in the 5-year history of this workshop. Herein, examples of the research that was presented are highlighted...